CORE

MSH

CAPACITY RESOURCE

• Boston University• FHI360• Overseas Strategic Consulting• Results for Development• International Law Institute-Africa Centre for

Legal Excellence• NEPAD

Ten regional organizations with range of PSS expertise

BuildingCapacity

• Brandeis University• Deloitte USA• Duke-National University of

Singapore• El Instituto de Evaluacion

Tecnologica en Salud• ePath• IC Consultants• Imperial Health Sciences• IQVIA• University of Washington

GLOBAL EXPERT

MTAPS TEAM OF TECHNICAL AND REGIONAL EXPERTS

Mohan Joshimjoshi@MTaPSprogram.org

For more information, contact:Technical lead for MTaPS GHSA/AMR activities USAID Senior Technical Advisors

Lisa Ludemaneludeman@usaid.gov

Tobey Buschtbusch@usaid.gov

Controlling the global hazard of antimicrobial resistance and supporting the Global Health Security Agenda rely on robust pharmaceutical systems worldwide.

PHOTO BY RUI PIRES

THE US AGENCY FOR INTERNATIONAL DEVELOPMENTMEDICINES, TECHNOLOGIES, AND PHARMACEUTICAL

SERVICES (MTaPS) PROGRAM

Improved Access. Improved Service. Better Health Outcomes.

Funded by the US Agency for International Development and led by Management Sciences for Health (MSH), the goal of the fi ve-year MTaPS program (2018–2023) is to help low- and middle-income countries strengthen their pharmaceutical systems to ensure sustainable access to and appropriate use of safe, effective, quality-assured, and affordable essential medicines and pharmaceutical services.

MTaPS will support the Global Health Security Agenda (GHSA), whose purpose is to help build countries’ capacity to protect themselves from infectious disease threats and to raise global health security as a national and global priority. The GHSA comprises 11

action packages, including one to combat antimicrobial resistance (AMR). MTaPS’ work will help GHSA target countries advance USAID’s AMR action package-related objectives.

MTaPS work in this area focuses on infection prevention and control (IPC) and optimizing antimicrobial use in human health, with the potential to work on animal health in the future.

MTaPS overall objectives1. Pharmaceutical sector governance strengthened

2. Institutional and human resource capacity for pharmaceutical management and services increased, including regulation of medical products

3. Availability and use of pharmaceutical information for decision making increased and global learning agenda advanced

4. Pharmaceutical sector fi nancing, including resource allocation and use, optimized

5. Pharmaceutical services, including product availability and patient-centered care, to achieve health outcomes improved

PHOTO BY RUI PIRES

GHSA target country challenges related to infection prevention and control and antimicrobial stewardshipIn both the human and animal-related sectors, stakeholders have limited capacity for and commitment to IPC and antimi-crobial stewardship (AMS); in addition, low- and middle-income countries generally have weak regulations, policies, guidelines, systems, and governance in these areas.

Examples of how MTaPS will collaborate with GHSA target countries to overcome challenges

Mobilize stakeholders and build coali-tions around IPC and AMS activities

Reform preservice and in-service curricula with a focus on One Health workforce core competencies

Educate patients and the public through customized materials/messages and the media

Build the capacity of journalists to intel-ligently report on IPC and AMS

Promote community-based activi-ties (e.g., through community health workers)

Help develop national and hospital-lev-el policies, guidelines, and standard operating procedures

Build capacity through tools, job aids, supportive supervision, and continuous quality improvement methods

Monitor adherence to recommended policies, guidelines, and practices

Incentivize rational prescribing and dispensing by health care providers

Improve capacity for antimicrobial-re-lated pharmacovigilance

Generate support to group antibiot-ics into AWARE (access, watch, and reserve) categories in national essential medicines lists following World Health Organization guidance

Strengthen regulatory capacity, includ-ing enforcement, to improve the use of antimicrobials

MTaPS will work with target countries to identify issues, players, and capacities and to prioritize and customize these activities to help them increase their IPC and AMS capac-ity based on Joint External Evaluation criteria.

MTaPS focus areas that broadly support AMR containment

Support for national action plans Multisectoral coalitions Public awareness of AMR Coordination with the GHSA Adaption of educational and implemen-

tation support tools Availability and use of antimicrobial-re-

lated data Support to drug and therapeutic

committees and continuous quality improvement methodologies

Curricular revision

MTaPS consortium MSH leads the MTaPS project consortium, comprising core, capacity resource, and global expert partners. Core and global expert partners are listed below and offer technical expertise to country assignments. Capacity resource partners include 10 local organizations with regional or country-based knowledge, expertise, and networks. Their engagement will support local MTaPS activities while advancing local capacity to provide PSS technical support at the country and regional levels.

MTaPS will draw on partner expertise to help countries meet their GHSA and AMR containment objectives.

Meeting the challenges of controlling AMR will require not only continued scale up of our successful strategies but also broader systems thinking and state-of-the art expertise.